In a move to satisfy regulators, Allergan has agreed to return the rights to inflammatory bowel disease therapy brazikumab to AstraZeneca and divest its gastrointestinal treatment Zenpep® (pancrelipase) to Nestle. Allergan first announced its intent to divest these two assets in August 2019 to remove potential overlaps in the combined company’s portfolio which already includes AbbVie’s competing therapies - Skyrizi® (risankizumab-rzaa) and Creon® (pancrelipase). In January 2020, the European Commission approved the AbbVie/Allergan transaction on the condition that Allergan divests brazikumab.